Future Integrative Medicine (FIM) is the official scientific journal of Capital Medical University. It promotes future innovation in medicine by actively integrating the best of traditional wisdom and modern scientific advancement. FIM publishes high-quality, peer-reviewed original research articles, reviews, opinions, commentaries, case reports, study protocols, and letters covering a wide range of topics that integrate conventional medicine with traditional, complementary, and alternative medicine, as well as nutrition- and food-based approaches to health and disease.  

FIM particularly welcomes research on functional foods, nutraceuticals, and medicine-food homology (MFH; Yaoshi Tongyuan) that bridges traditional dietary wisdom with modern evidence-based medicine. This includes functional foods, medicinal and edible resources, functional ingredients, traditional dietary therapies, and their applications in disease prevention, health promotion, personalized medicine, and integrative care.  

FIM recognizes that the modernization and future development of traditional and integrative medicine rely on the rigorous application of modern medical science and cutting-edge biomedical technologies. The journal therefore welcomes studies applying advanced techniques, including molecular biology, biochemistry, immunology, genomics, proteomics, metabolomics, advanced imaging, and systems biology, to investigate the efficacy, safety, mechanisms, and clinical translation of traditional, nutritional, and food-based interventions. Topics of special interest include:  

• Application of modern medical diagnostics and therapeutics within integrative medicine frameworks.
• Evidence-based studies of traditional Chinese medicine, other traditional and complementary therapies, dietary supplements, nutraceuticals, functional foods, and other non-drug interventions.
• Medicine-food homology, including functional foods, medicinal and edible resources, functional ingredients, and traditional dietary therapies.
• Mechanistic, clinical, epidemiological, and translational studies of food-derived bioactive compounds and food-based interventions for disease prevention and management.
• Diet–microbiota interactions, gut microbiome, precision nutrition, and related approaches relevant to integrative medicine and human health.
• Efficacy- and safety-guided biomarker research employing advanced analytical techniques.
• Pharmacological characterization, safety evaluation, standardization, and quality control of bioactive substances and natural products.
• Molecular mechanism studies. Computational and in silico studies should be supported by appropriate experimental or clinical validation when making mechanistic or therapeutic claims.

Future Integrative Medicine (FIM) adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

FIM recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

All manuscripts submitted to FIM must meet the following criteria for publication:

• Topics with timely relevance to the general field or specialties in basic and clinical medicine;
• A must-have section of “hypothesis/ future direction/ prospect/ prediction” included for all research and review articles;
• Results and findings that have not been previously published elsewhere;
• Research performed with adherence to accepted global standards for ethics in the scientific process;
• Ethical reporting of data to protect the rights and privacy of study participants;
• Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
• Conclusions supported by the data presented;
• All funding sources and their roles cited;
• For clinical trials, the registration number cited;
• Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
• No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.

FIM currently publishes 4 issues a year, in March, June, September and December.

FIM follows an open access publishing model. Revenue is generated through article processing charges, permissions, and reprints. Currently, the publication costs are covered by the publisher.